Press Releases

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

April 30, 2018

AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference

Gallagher highlights the groundbreaking clinical trial, HOPE4MCI, which could slow progression from Mild Cognitive Impairment to Alzheimer’s dementia LOS ANGELES, April 30, 2018 — Today, AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook.…

February 28, 2018

AgeneBio to Speak at ASENT 2018 Annual Meeting

Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…

February 28, 2018

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…

July 24, 2017

AgeneBio Founder Presents at Alzheimer’s Association International Conference

Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.”   Details available here.

February 17, 2016

AgeneBio to Present at Neuroscience BioPartnering & Investment Forum

Baltimore, MD, February 17, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at the Neuroscience BioPartnering & Investment Forum. CEO Jerry McLaughlin will present a overview of AgeneBio‘s work in…

February 2, 2016

AgeneBio to Present at BIO CEO & Investor Conference

Baltimore, MD, February 2, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at BIO CEO & Investor Conference. CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at…

December 15, 2015

AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website

Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling…